capitaLand also circling?, page-24

First 24 Last

Share
Profile

Follow
angor532

23,660 Posts.

380

20/02/22

19:47

Post #: 59691365
Share

Originally posted by rcman: ↑

Investors in the AMP Capital Wholesale Office Fund are expected to flex their muscles in the weeks ahead as AMP explores a sale of Collimate Capital Funds Management instead of pursuing a merger.

Investors in the fund were already unhappy with AMP when it was known to be only heading towards a demerger of the unit, previously known as AMP Capital.

But some question how staff and investors will react, now that AMP is understood to be considering a sale of some or all of the business.

While delivering its results recently AMP confirmed it was talking to prospective buyers of the fund, which some believe left the AWOF investors blindsided.

Investor unease centres on corporate governance and a controversial process run last year to determine whether Collimate should remain at the helm of the fund.

The fund is considered the jewel in Collimate’s crown, with more than $7bn worth of offices under its control, including the prestigious Quay Quarter in Sydney and Melbourne’s Collins Place.

Investors, including big super funds, wrote to the trustee board of AWOF through law firm Allens, raising concerns about conflicts of interest in the process.

Some sources believe all of the investors backed the letter except UniSuper, which was keen to see its funds remain under AMP’s control.

Investors have the option to call a meeting to dump AMP as manager, but the complication is that the constitution says this can only happen if it has another manager to nominate as a replacement, says a source.

Any party wanting to take on the management of the fund would want to first conduct due diligence.

Last year, an independent advisory board was formed including high-profile names such as the former Future Fund real estate head Barry Brakey, Wesfarmers director Sharon Warburton and property veteran Paul Say, but they resigned abruptly. The suggestion at the time was they departed after the AWOF trustee board did not accept their recommendations to replace AMP as manager with a rival such as GPT or Mirvac.

A source said AMP changed the nature of the review from considering whether it should be replaced to whether it was doing its job appropriately as the manager of the fund. The trustee board then brought in two other independents – Ming Long and Bob McKinnon.

But this move was criticised by AWOF investors because they held non-executive roles in the broader AMP empire and for that reason were not perceived to be independent.

Expand

yup...unisuper 35% owner of fund.... suck on that "other investor" jag offs!!!..

Unisuper loves blue horseshoe AMP!..

AMP Price at posting: $1.02 Sentiment: None Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

There are more pages in this discussion • 95 more messages in this thread...

First 24 Last

Add AMP (ASX) to my watchlist

(20min delay)
Last $1.33		Change 0.005(0.38%)		Mkt cap ! $3.374B

Open	High	Low	Value	Volume
$1.33	$1.34	$1.32	$5.738M	4.332M

Buyers (Bids)

No.	Vol.	Price($)
59	332828	$1.32

Sellers (Offers)

Price($)	Vol.	No.
$1.33	117181	25

View Market Depth

No.	Vol.	Price($)
81	283363	1.325
38	345906	1.320
19	313641	1.315
15	246990	1.310
17	269695	1.305

Price($)	Vol.	No.
1.330	427550	42
1.335	287020	20
1.340	238171	20
1.345	203077	18
1.350	1058368	80

Last trade - 15.09pm 07/10/2024 (20 minute delay)

AMP (ASX) Chart

capitaLand also circling?, page-24

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

capitaLand also circling?, page-24

Top Stories

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News